tegafur has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not." | 1.91 | Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy. ( Doi, T; Funakoshi, Y; Hojo, W; Hokka, D; Maniwa, Y; Minami, H; Mitsui, S; Nishikubo, M; Ohji, G; Sakai, H; Tanaka, Y; Yakushijin, K, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikubo, M | 1 |
| Tanaka, Y | 1 |
| Mitsui, S | 1 |
| Doi, T | 1 |
| Hokka, D | 1 |
| Hojo, W | 1 |
| Sakai, H | 1 |
| Funakoshi, Y | 1 |
| Yakushijin, K | 1 |
| Ohji, G | 1 |
| Minami, H | 1 |
| Maniwa, Y | 1 |
1 other study available for tegafur and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur-uracil as postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2023 |